Shenzhen International Institute for Biomedical Research (SIIBR) is a non-profit biomedical research unit, established since January 2015, is led by Professor Benard Roizman. The core leadership team of SIIBR consists of 6 pioneering medical-microbiology scientists and academicians from Harvard University, University of Chicago and Princeton University in the States. The research focus of SIIBR is in cancer and acute and chronic microbial infection. SIIBR will introduce innovative biomedical and biopharmaceutical projects with prospects of industrialization, e.g. oncolytic- and immuno- dual therapy of solid tumors; immunotherapy of drug-resistant super-bug; sensitive treatment of radiation-resistant tumour; nasopharyngeal carcinoma immunotherapy; new drug development for acute and latent viral infection etc...